SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
14.8 EUR
-0.22 (-1.46%)
Overall 1SXP gets a fundamental rating of 6 out of 10. We evaluated 1SXP against 22 industry peers in the Life Sciences Tools & Services industry. 1SXP scores excellent on profitability, but there are some minor concerns on its financial health. 1SXP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year 1SXP was profitable.
- 1SXP had a positive operating cash flow in the past year.
- Each year in the past 5 years 1SXP has been profitable.
- Each year in the past 5 years 1SXP had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 9.16%, 1SXP belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
- 1SXP's Return On Equity of 16.42% is amongst the best of the industry. 1SXP outperforms 86.36% of its industry peers.
- The Return On Invested Capital of 1SXP (13.06%) is better than 90.91% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is significantly above the industry average of 9.34%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROIC | 13.06% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1.3 Margins
- 1SXP's Profit Margin of 14.85% is fine compared to the rest of the industry. 1SXP outperforms 72.73% of its industry peers.
- In the last couple of years the Profit Margin of 1SXP has grown nicely.
- 1SXP has a better Operating Margin (18.95%) than 77.27% of its industry peers.
- 1SXP's Operating Margin has improved in the last couple of years.
- With a Gross Margin value of 33.71%, 1SXP is not doing good in the industry: 68.18% of the companies in the same industry are doing better.
- 1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% |
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
2. Health
2.1 Basic Checks
- 1SXP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
- The number of shares outstanding for 1SXP remains at a similar level compared to 5 years ago.
- 1SXP has a better debt/assets ratio than last year.
2.2 Solvency
- The Debt to FCF ratio of 1SXP is 2.43, which is a good value as it means it would take 1SXP, 2.43 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of 1SXP (2.43) is better than 90.91% of its industry peers.
- 1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- 1SXP has a better Debt to Equity ratio (0.09) than 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | N/A |
ROIC/WACC1.38
WACC9.44%
2.3 Liquidity
- A Current Ratio of 1.50 indicates that 1SXP should not have too much problems paying its short term obligations.
- 1SXP has a Current ratio of 1.50. This is in the better half of the industry: 1SXP outperforms 63.64% of its industry peers.
- A Quick Ratio of 1.12 indicates that 1SXP should not have too much problems paying its short term obligations.
- 1SXP has a Quick ratio of 1.12. This is comparable to the rest of the industry: 1SXP outperforms 59.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- The earnings per share for 1SXP have decreased by -2.02% in the last year.
- 1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.78% yearly.
- The Revenue has been growing slightly by 3.04% in the past year.
- Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 11.04% on average per year.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
3.2 Future
- The Earnings Per Share is expected to grow by 12.98% on average over the next years. This is quite good.
- 1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.13% yearly.
EPS Next Y2.98%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
EPS Next 5Y12.98%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 15.26 indicates a correct valuation of 1SXP.
- 90.91% of the companies in the same industry are more expensive than 1SXP, based on the Price/Earnings ratio.
- 1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 27.21, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 14.82 indicates a correct valuation of 1SXP.
- Based on the Price/Forward Earnings ratio, 1SXP is valued cheaper than 90.91% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 25.98, 1SXP is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.26 | ||
| Fwd PE | 14.82 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, 1SXP is valued cheaper than 90.91% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than the industry average as 63.64% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 63.39 | ||
| EV/EBITDA | 8.64 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- 1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)5.12
PEG (5Y)1.11
EPS Next 2Y8.11%
EPS Next 3Y9.33%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.19%, 1SXP has a reasonable but not impressive dividend return.
- In the last 3 months the price of 1SXP has falen by -23.79%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
- Compared to an average industry Dividend Yield of 0.48, 1SXP pays a better dividend. On top of this 1SXP pays more dividend than 90.91% of the companies listed in the same industry.
- Compared to the average S&P500 Dividend Yield of 1.81, 1SXP is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.19% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- 1SXP pays out 16.45% of its income as dividend. This is a sustainable payout ratio.
DP16.45%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status for 1SXP stock?
ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for 1SXP stock?
The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 6 / 10.
What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?
The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 2.98% in the next year.